X

Drug Profile

Research programme: subtype-selective NMDA receptor antagonists - Purdue Pharma/Senju

Latest Information Update: 03 Sep 2007

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer; Purdue Pharma
Developer Purdue Pharma; Senju Pharmaceutical
Class
Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cerebral ischaemia; Epilepsy; Eye disorders; Neurological disorders; Pain; Parkinson's disease

Most Recent Events

21 Jun 2000 Warner-Lambert has merged with Pfizer
16 Nov 1999 CoCensys has been acquired by Purdue Pharma
27 May 1999 A lead compound from this programme has been identified

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com